Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Spotlight (1) Saha D (2) Martuza RL (3) Rabkin SD
Using a non-immunogenic, intracranial glioblastoma stem-like cell tumor and the more aggressive CT-2A model, Saha et al. show that the triplet of an IL-12 expressing oncolytic herpes virus, anti-CTLA-4, and anti-PD-1 checkpoint therapy led to significant long term survival and resistance to re-challenge, overcoming multiple forms of immunosuppression. Noteworthy were the criticality of CD4+ T cells, near criticality of CD8+ cells, and the increase in M1-polarized tumor associated macrophages.
(1) Saha D (2) Martuza RL (3) Rabkin SD
Using a non-immunogenic, intracranial glioblastoma stem-like cell tumor and the more aggressive CT-2A model, Saha et al. show that the triplet of an IL-12 expressing oncolytic herpes virus, anti-CTLA-4, and anti-PD-1 checkpoint therapy led to significant long term survival and resistance to re-challenge, overcoming multiple forms of immunosuppression. Noteworthy were the criticality of CD4+ T cells, near criticality of CD8+ cells, and the increase in M1-polarized tumor associated macrophages.
Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV G47Delta expressing murine IL-12 (G47Delta-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations modestly extended survival of a mouse glioma model. However, the triple combination of anti-CTLA-4, anti-PD-1, and G47Delta-mIL12 cured most mice in two glioma models. This treatment was associated with macrophage influx and M1-like polarization, along with increased T effector to T regulatory cell ratios. Immune cell depletion studies demonstrated that CD4+ and CD8+ T cells as well as macrophages are required for synergistic curative activity. This combination should be translatable to the clinic and other immunosuppressive cancers.
Author Info: (1) Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery,
Author Info: (1) Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Harvard Medical School, Boston, MA, USA. (2) Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Harvard Medical School, Boston, MA, USA. (3) Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Harvard Medical School, Boston, MA, USA. Electronic address: rabkin@mgh.harvard.edu.
Citation: Cancer Cell 2017 Aug 14 32:253-267.e5 Epub